TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has granted equity incentives to 14 new employees as employment inducements. The compensation package includes 21,458 non-qualified stock options with an exercise price of $105.24 per share and 14,283 restricted stock units (RSUs).
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group, Inc. Inducement Plan.
TransMedics (NASDAQ: TMDX), un'azienda di tecnologia medica specializzata nella terapia per il trapianto di organi, ha concesso incentivi azionari a 14 nuovi dipendenti come incentivo all'assunzione. Il pacchetto retributivo comprende 21.458 opzioni azionarie non qualificate con un prezzo di esercizio di $105,24 per azione e 14.283 unit脿 azionarie vincolate (RSU).
Le opzioni azionarie matureranno per il 25% dopo un anno, con il restante che maturer脿 mensilmente nel corso di tre anni. Le RSU matureranno per il 25% ogni anno per quattro anni. Entrambe le assegnazioni richiedono il mantenimento dell'impiego e sono state approvate secondo la Regola Nasdaq Listing 5635(c)(4) tramite il TransMedics Group, Inc. Inducement Plan.
TransMedics (NASDAQ: TMDX), una empresa de tecnolog铆a m茅dica enfocada en la terapia de trasplante de 贸rganos, ha otorgado incentivos de acciones a 14 nuevos empleados como est铆mulo para su contrataci贸n. El paquete de compensaci贸n incluye 21,458 opciones sobre acciones no calificadas con un precio de ejercicio de $105.24 por acci贸n y 14,283 unidades restringidas de acciones (RSU).
Las opciones sobre acciones se consolidar谩n en un 25% despu茅s de un a帽o, con el resto consolid谩ndose mensualmente durante tres a帽os. Las RSU se consolidar谩n en un 25% anual durante cuatro a帽os. Ambas concesiones requieren empleo continuo y fueron aprobadas bajo la Regla de Listado Nasdaq 5635(c)(4) a trav茅s del Plan de Est铆mulos de TransMedics Group, Inc.
TransMedics (NASDAQ: TMDX)電� 鞛リ赴 鞚挫嫕 旃橂鞐� 欷戩爯鞚� 霊� 鞚橂 旮办垹 須岇偓搿�, 14氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 毂勳毄 鞙犾澑毂呾溂搿� 欤检嫕 鞚胳劶韹半笇毳� 攵�鞐枅鞀惦媹雼�. 氤挫儊 韺偆歆�鞐愲姅 欤茧嫻 $105.24鞚� 頄夓偓 臧�瓴╈潉 臧�歆� 21,458臧滌潣 牍勳瀽瓴� 欤检嫕 鞓奠厴瓿� 14,283臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
欤检嫕 鞓奠厴鞚� 1雲� 頉� 25%臧� 甓岆Μ 旆摑霅橂┌, 雮橂ǜ歆�電� 3雲勳棎 瓯胳硱 毵れ洈 甓岆Μ 旆摑霅╇媹雼�. RSU電� 4雲勳棎 瓯胳硱 毵る厔 25%鞌� 甓岆Μ 旆摑霅╇媹雼�. 霊� 氤挫儊 氇憪 瓿勳啀 瓿犾毄鞚� 臁瓣贝鞙茧 頃橂┌, 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 TransMedics Group, Inc. 鞙犾澑毂� 瓿勴殟鞚� 韱淀暣 鞀轨澑霅橃棃鞀惦媹雼�.
TransMedics (NASDAQ : TMDX), une entreprise de technologie m茅dicale sp茅cialis茅e dans la th茅rapie de transplantation d'organes, a accord茅 des incitations en actions 脿 14 nouveaux employ茅s en tant qu'incitatifs 脿 l'embauche. Le package de r茅mun茅ration comprend 21 458 options d'achat d'actions non qualifi茅es avec un prix d'exercice de 105,24 $ par action et 14 283 unit茅s d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises 脿 hauteur de 25 % apr猫s un an, le reste 茅tant acquis mensuellement sur trois ans. Les RSU seront acquises 脿 raison de 25 % par an sur quatre ans. Les deux attributions n茅cessitent une poursuite de l'emploi et ont 茅t茅 approuv茅es conform茅ment 脿 la r猫gle Nasdaq Listing 5635(c)(4) via le plan d'incitation de TransMedics Group, Inc.
TransMedics (NASDAQ: TMDX), ein Medizintechnologieunternehmen mit Schwerpunkt auf Organtransplantationstherapie, hat 14 neuen Mitarbeitern als Anreiz zur Einstellung Aktienanreize gew盲hrt. Das Verg眉tungspaket umfasst 21.458 nicht qualifizierte Aktienoptionen mit einem Aus眉bungspreis von 105,24 $ pro Aktie und 14.283 Restricted Stock Units (RSUs).
Die Aktienoptionen werden zu 25 % nach einem Jahr f盲llig, der Rest wird 眉ber drei Jahre monatlich freigegeben. Die RSUs werden j盲hrlich zu 25 % 眉ber vier Jahre freigegeben. Beide Zuteilungen erfordern eine fortgesetzte Besch盲ftigung und wurden gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) durch den TransMedics Group, Inc. Inducement Plan genehmigt.
- None.
- None.
TransMedics granted non-qualified stock options to purchase 21,458 shares of TransMedics' common stock and 14,283 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of
About TransMedics Group, Inc.听
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in
Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
[email protected]听
View original content to download multimedia:
SOURCE TransMedics Group, Inc.
FAQ
What equity incentives did TransMedics (TMDX) grant to new employees in July 2025?
What is the vesting schedule for TransMedics (TMDX) employee stock options granted in July 2025?
What is the vesting schedule for TransMedics (TMDX) restricted stock units granted in July 2025?
What was the exercise price for TransMedics (TMDX) stock options granted in July 2025?
